Identifying epidermal growth factor receptor mutation status in patients with lung adenocarcinoma by three-dimensional convolutional neural networks.

OBJECTIVE: Genetic phenotype plays a central role in making treatment decisions of lung adenocarcinoma, especially the tyrosine-kinase-inhibitors-sensitive mutations of the epidermal growth factor receptor (EGFR) gene. We constructed three-dimensional convolutional neural networks (CNN) to analyze underlying patterns in CT images that could indicate that EGFR gene mutation status but are invisible to human eyes. METHODS: From 2012 to 2015, 503 Chinese patients with lung adenocarcinoma that had underwent surgery were included. Pathological types and EGFR mutation status were tested from surgical resections. EGFR mutations (exon 19 deletion or exon 21 L858R) were found in 215/345 (62.3%) and 91/158 (57.6%) patients in the training and independent validation set, respectively. CT images were taken before any invasive operation. The patients were randomly chosen to train the CNNs or validate the CNNs' performance. The performance was quantified using area under receiver operating characteristic curve (AUC), sensitivity, specificity, and accuracy. RESULTS: The CNNs showed an AUC of 0.776 (range: 0.702-0.849, p< 0.0001) in the independent validation set and a fusion model of CNNs and clinical features (sex and smoking history) showed an AUC of 0.838 (range: 0.778-0.899, p< 0.0001), accuracy of 77.2%, sensitivity of 75.8% and specificity of 79.1% at the best diagnostic decision point. CONCLUSION: The CNN exhibits potential ability to identify EGFR mutation status in patients with lung adenocarcinoma which might help make clinical decisions. ADVANCES IN KNOWLEDGE: The CNN showed some diagnostic power and its performance could be further improved by increasing the training set, optimizing the network structure and training strategy. Medical image based CNN has the potential to reflect spatial heterogeneity.

[1]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[2]  Y. Liu,et al.  Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas. , 2016, Clinical lung cancer.

[3]  Hao Chen,et al.  Multilevel Contextual 3-D CNNs for False Positive Reduction in Pulmonary Nodule Detection , 2017, IEEE Transactions on Biomedical Engineering.

[4]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[5]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[6]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[7]  P. Jänne,et al.  Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses , 2015, Clinical Cancer Research.

[8]  Zijuan Zhao,et al.  MLW-gcForest: a multi-weighted gcForest model towards the staging of lung adenocarcinoma based on multi-modal genetic data , 2019, BMC Bioinformatics.

[9]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Sebastian Thrun,et al.  Dermatologist-level classification of skin cancer with deep neural networks , 2017, Nature.

[11]  Paul Kinahan,et al.  Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.

[12]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[13]  Mehmet Toner,et al.  Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.

[14]  Zhi Zheng,et al.  Determination of EGFR mutations in single cells microdissected from enriched lung tumor cells in peripheral blood , 2013, Analytical and Bioanalytical Chemistry.

[15]  W. Tsai,et al.  Reproducibility of radiomics for deciphering tumor phenotype with imaging , 2016, Scientific Reports.

[16]  R. Gillies,et al.  MO-DE-207B-08: Radiomic CT Features Complement Semantic Annotations to Predict EGFR Mutations in Lung Adenocarcinomas. , 2016, Medical physics.

[17]  Xiang Hu,et al.  Predictive models for patients with lung carcinomas to identify EGFR mutation status via an artificial neural network based on multiple clinical information , 2019, Journal of Cancer Research and Clinical Oncology.

[18]  Yi Liu,et al.  Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer. , 2015, The Journal of molecular diagnostics : JMD.

[19]  Y. Yatabe,et al.  Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer , 2007, Cancer science.